3-(2-bromo-4-hydroxyphenyl)-7-hydroxy-2H-chromen-2-one (SZC-6) is a novel SIRT3 activator that occupied allosite binding pocket of SIRT3 protein with high affinity. The cover art describes that SZC-6 showed significant protective effects on mitochondria, which would create a brighter future for new treatments for cardiac hypertrophy.

Schematic models of 14-deoxygarcinol (DOG) in attenuating adipose tissue inflammation. Therapeutically, DOG activates SIRT2 to suppress NF-κB/NLRP3 inflammasome-mediated IL-1β secretion, which in turn alleviates adipose tissue inflammation and improves insulin sensitivity.

Schematic depicting the preparation of a dual-responsive nanoparticle BCGN and its mechanisms in treating non-small-cell lung cancer (NSCLC). The BCGN are responsive to oxidation and reduction for triggering drug release at different conditions. It provides a promising strategy to improve combinational molecular targeted therapy against NSCLC.